Kura Oncology Inc (KURA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.91 is considered Undervalued compared with the five-year average of -6.29. The fair price of Kura Oncology Inc (KURA) is between 70.39 to 73.14 according to relative valuation method. Compared to the current price of 8.68 USD , Kura Oncology Inc By Undervalued By 87.67%.

Relative Value

Fair Zone

70.39-73.14

Current Price：8.68

87.67%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Kura Oncology Inc (KURA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Kura Oncology Inc (KURA) has a current Price-to-Book (P/B) ratio of 3.71. Compared to its 3-year average P/B ratio of 2.40, the current P/B ratio is approximately 54.54% higher. Relative to its 5-year average P/B ratio of 2.34, the current P/B ratio is about 58.59% higher. Kura Oncology Inc (KURA) has a Forward Free Cash Flow (FCF) yield of approximately 9.24%. Compared to its 3-year average FCF yield of -4.08%, the current FCF yield is approximately -326.26% lower. Relative to its 5-year average FCF yield of -6.36%, the current FCF yield is about -245.28% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for KURA competitors is 128.32, providing a benchmark for relative valuation. Kura Oncology Inc Corp (KURA.O) exhibits a P/S ratio of 3.91, which is -96.96% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of KURA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of KURA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is KURA currently overvalued or undervalued?

What is Kura Oncology Inc (KURA) fair value?

KURA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Kura Oncology Inc (KURA) is between 70.39 to 73.14 according to relative valuation method.

How does KURA's valuation metrics compare to the industry average?

The average P/S ratio for KURA's competitors is 128.32, providing a benchmark for relative valuation. Kura Oncology Inc Corp (KURA) exhibits a P/S ratio of 3.91, which is -96.96% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Kura Oncology Inc (KURA) as of Mar 03 2026?

As of Mar 03 2026, Kura Oncology Inc (KURA) has a P/B ratio of 3.71. This indicates that the market values KURA at 3.71 times its book value.

What is the current FCF Yield for Kura Oncology Inc (KURA) as of Mar 03 2026?

As of Mar 03 2026, Kura Oncology Inc (KURA) has a FCF Yield of 9.24%. This means that for every dollar of Kura Oncology Inc's market capitalization, the company generates 9.24 cents in free cash flow.

What is the current Forward P/E ratio for Kura Oncology Inc (KURA) as of Mar 03 2026?

As of Mar 03 2026, Kura Oncology Inc (KURA) has a Forward P/E ratio of -4.11. This means the market is willing to pay $-4.11 for every dollar of Kura Oncology Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Kura Oncology Inc (KURA) as of Mar 03 2026?

As of Mar 03 2026, Kura Oncology Inc (KURA) has a Forward P/S ratio of 3.91. This means the market is valuing KURA at $3.91 for every dollar of expected revenue over the next 12 months.

KURA Valuation